Cancer chemotherapy and biological response modifiers annual 22 / edited by G. Gianccone, R. Schilsky, P. Sondel

Contents
Introduction
I. Drugs
1. Thymidylates synthase inhibitors
2. Anthracyclines
3. Tubulin-targeting agents
4. Recent developments in the clinical activity of topoisomerase-1 inhibitors
5. Topoisomerase II inhibitors
6. Farnesyltransferase inhibitors
7. Cyclin-depent kinases as targets for cancer therapy
8. DNA-binding agents
9. Epidermal growth factor receptor pathway inhibitors
10. Angiogenesis pathway inhibitors

II. Biological Response Modifiers
11. Prostate cancer antigens and vaccines, preclinical developments
12. Systemic therapy for renal cell carcinoma
13. Retargeting T cells and immune effector cells with bispecific antibodies
14. T cells genetic modification for re-directed tumor recognition
15. Cancer therapy-induced immune modulation

III. Tumours
16. Plasma cell dyscrasias and leukemias
17. Lymphomas
18. Head and neck cancer
19. Lung cancer
20. Cancers of the large bowel annd hepatobiliart tract
21. Neuroendocrine tumours
22. Genitourinary Malignancies
23. Systemic therapy for gynecological neoplasms: ovary, cervix, and endometrium
24. Breast cancer
25. Maelanoma
26. soft-tissue and bone sarcomas
27. Central nervous system tumors
28.Biology and Therapy of Malignant solids tumors in childhood
29.Supportive Care
30.AIDS - associated malignancies


IV. Melanoma and biological response modifiers in the treatment of Melaanoma
31. Genetics, prevention and screening for melanoma
32. Current status of interferon- in the treatment of melanoma
33. Chemotherapy, cytokines and biochemotherapy for melanoma
34. Immunizing against partially defined antigen mixtures, gangliosides, or peptides to induce antibody, T cell and clinical responses
35. DNA vaccines for melanoma
36. Human tumor
37. Native and genetically engineered anti-disialoganglioside monolonal antibody treatment of melanoma

Includes Bibliographical references and index

Contents
Introduction
I. Drugs
1. Thymidylates synthase inhibitors
2. Anthracyclines
3. Tubulin-targeting agents
4. Recent developments in the clinical activity of topoisomerase-1 inhibitors
5. Topoisomerase II inhibitors
6. Farnesyltransferase inhibitors
7. Cyclin-depent kinases as targets for cancer therapy
8. DNA-binding agents
9. Epidermal growth factor receptor pathway inhibitors
10. Angiogenesis pathway inhibitors

II. Biological Response Modifiers
11. Prostate cancer antigens and vaccines, preclinical developments
12. Systemic therapy for renal cell carcinoma
13. Retargeting T cells and immune effector cells with bispecific antibodies
14. T cells genetic modification for re-directed tumor recognition
15. Cancer therapy-induced immune modulation

III. Tumours
16. Plasma cell dyscrasias and leukemias
17. Lymphomas
18. Head and neck cancer
19. Lung cancer
20. Cancers of the large bowel annd hepatobiliart tract
21. Neuroendocrine tumours
22. Genitourinary Malignancies
23. Systemic therapy for gynecological neoplasms: ovary, cervix, and endometrium
24. Breast cancer
25. Maelanoma
26. soft-tissue and bone sarcomas
27. Central nervous system tumors
28.Biology and Therapy of Malignant solids tumors in childhood
29.Supportive Care
30.AIDS - associated malignancies


IV. Melanoma and biological response modifiers in the treatment of Melaanoma
31. Genetics, prevention and screening for melanoma
32. Current status of interferon- in the treatment of melanoma
33. Chemotherapy, cytokines and biochemotherapy for melanoma
34. Immunizing against partially defined antigen mixtures, gangliosides, or peptides to induce antibody, T cell and clinical responses
35. DNA vaccines for melanoma
36. Human tumor
37. Native and genetically engineered anti-disialoganglioside monolonal antibody treatment of melanoma